Ignite Creation Date:
2024-05-06 @ 2:00 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01947608
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2020-11-03
First Post:
2013-09-17
Brief Title:
Expanded Treatment Protocol With LDK378 in ALK NSCLC
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-label Multi-center Expanded Treatment Protocol ETP of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer NSCLC Characterized by ALK Positivity
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Novartis-sponsored open-label multi-center interventional ETP to provide LDK378 to patients with ALK NSCLC who have been pre-treated with an ALK inhibitor except in countries where ALK inhibitors are not approved or available The protocol will further evaluate the safety of LDK378 in patients with ALK NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None